Preview

Научно-практическая ревматология

Расширенный поиск

ИНГИБИТОРЫ ФНО-α И ИХ ВЛИЯНИЕНА ФАКТОРЫ РИСКА ПОРАЖЕНИЯ СЕРДЕЧНО-СОСУДИСТОЙСИСТЕМЫ У ПАЦИЕНТОВ С РЕВМАТОИДНЫМ АРТРИТОМ

https://doi.org/10.14412/1995-4484-2010-1401

Полный текст:

Список литературы

1. <div><p>Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology 2005;44:1473-82.</p><p>Goodson N.J., Wiles N.J., Lunt M. et al. Mortality in early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-19.</p><p>Leuven S.I., Franssen R., Kastelein J.J. et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008;47:3-7.</p><p>Насонов Е.Л. Иммунологические маркеры атеросклероза. Тер арх 2002;5:80-5.</p><p>Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.</p><p>Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004.</p><p>Gonzalez A., Kremers M.H., Crowson C.S. et al. Survival trends and risk factors for mortality in rheumatoid arthritis. Int J Аdv in Rheumatol 2005;3:38-46.</p><p>Radovits B.J., Popa-Diaconu D.A., Popa C. et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2008;8:10-15.</p><p>Bartoloni B.E., Marchesi S., Delle Monache F. et al. Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity. Rheumatismo 2005;57(1):16-21.</p><p>Vaudo G., Marchesi S., Gerli R. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63(1):31-5.</p><p>Kremers M.H., Crowson C., Nicola P. et al. Increased unrecognized coronary heart disease and sudden deaths rheumatoid arthritis. A population-based controlled study. Arthritis Rheum 2005;52:402-11.</p><p>Nielen M.J., van Halm V.P., Numohamed M.T. et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthritis Rheum 2003;48:344-50.</p><p>Goodson N.J., Symmons D.P., Scott D.I. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis. Arthritis Rheum 2005;52(8):2293-9.</p><p>Попкова Т.В., Хелковская А.Н., Мач Э.С. и др. Сердечно-сосудистые заболевания при ревматоидном артрите. Тер арх 2007;5:9-14.</p><p>Del Rincon I., Williams K., Stern M. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48(7):1833-40.</p><p>Gonzalez-Juanatey C., Liorca J., Testa A. et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003;82:407-13.</p><p>Nagata-Sakurai M., Inaba M., Goto H. et al. Inflammation and bone resorbtion as independent factors of accelerated arterial</p><p>Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006;18(3):289-97.</p><p>Peterson M.J., Symmons D.P., McCarrey D.W. et al. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - EULAR TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2008;67(Suppl. II):310.</p><p>Choi H.K., Hernan M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.</p><p>Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 647-60.</p><p>Кардиология: национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2007; 1232 с.</p><p>Hurliman D., Forster A., Noll G. et al. Anti-tumor necrosis factor-alfa treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7.</p><p>Gonzalez-Juanatey С., Testa A., Garcia-Castelo A. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor-alfa antibody. Arthritis Rheum 2004;51:447-50.</p><p>Irace C., Mancuso G., Fiaschi E. et al. Effect of anti TNF alfa therapy on arterial diametr and wall shear stress and HDL cholesterol. Atherosclerosis 2004;177:113-8.</p><p>Vis M., Nurmohamed M.T., Wolbink G. et al. Short-term effects on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-5.</p><p>Popa C., Radstake T., Netea M.G. et al. Influence of anti-tumor necrosis factor-alfa therapy on cardiovascular risk factors in patients with actiwe rheumatoid. Ann Rheum Dis 2005;64:303-5.</p><p>Popa C., Radstake T., Netea M.G. et al. Long-term anti TNF alfa therapy effect on lipoprotein concentrations in patients with actiwe rheumatoid arthritis (abstract). Arthritis Rheum 2006;54:9.</p><p>Spanakis E., Sidiropouls P., Papadakis J. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflamatory arthritides treated with Infliximab. J Rheumatol 2006;33:12.</p><p>Kiortsis D.N., Mavridis A.K. Effects of infliximab lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheum Dis 2006;33:4921-3.</p><p>Cauza E., Cauza K., Hanusch-Ensener U. et al. Intravenosus anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002;114:1004-7.</p><p>Dominguenz H., Storaard H., Rask-Madsen C. et al. Metabolic and vascular effects of tumor-alpha blockades with atanarcept in obese patients with type 2 diabetes. J Vasc Res 2005;42:517-25.</p><p>Kiortsis D.N., Mavridis A.K. Effects of infliximab on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765-6.</p><p>Gonzales-Gay M.A., De Matias J.M., Gonzalez-Juanatey C. et al. Anti-tumor factor-alpha blockade improvers insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6.</p><p>Gonzalez-Juanatey C., Liorca J., Garcia-Porrua C. et al. Effect of anti-tumor necrosis factor-alpha therapy on the progression of subclinical aterosclerosis in severe rheumatoid arthritis. Arhritis Rheum 2006;55:150-3.</p><p>Del Porto F., Lagana B., Lai S. et al. Response to anti-tumor necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007;46:1111-5.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.</p><p>Dixon W.G., Watson K.D., Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.</p><p>Jacobsson L.T., Askling J., Rantapaa-Dahlgvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS). Ann Rheum Dis 2008;67(Suppl. II):183.</p><p>Jacobsson L.T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8.</p><p>Solomon D.H., Avorn J., Katz J.N. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8.</p><p>Chung E.S., Packer M., Lo K.H. et al. Randomized, double-blind, placebo controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alfa, in patients with moderate-to-severe heart failure results of the anti-TNF Therapy Againts Congestive Heart Failure(ATTACH) trial. Circulation 2003;107:3133-40.</p><p>Kwon H.J., Cote T.R., Cuffe M.S. et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.</p></div><br />


Для цитирования:


Lineva O.G., Попкова Т.В., Новикова Д.С., Насонов Е.Л., Lineva O.G., Попкова Т.В., Новикова Д.С., Насонов Е.Л. ИНГИБИТОРЫ ФНО-α И ИХ ВЛИЯНИЕНА ФАКТОРЫ РИСКА ПОРАЖЕНИЯ СЕРДЕЧНО-СОСУДИСТОЙСИСТЕМЫ У ПАЦИЕНТОВ С РЕВМАТОИДНЫМ АРТРИТОМ. Научно-практическая ревматология. 2010;48(1):15-19. https://doi.org/10.14412/1995-4484-2010-1401

For citation:


Lineva O.G., Popkova T.V., Novikova D.S., Nasonov E.L., Lineva O.G., Popkova T.V., Novikova D.S., Nasonov E.L. Tumor necrosis factor-α inhibitors and their effects on cardiovascular risk factorsin patients with rheumatoid arthritis. Rheumatology Science and Practice. 2010;48(1):15-19. (In Russ.) https://doi.org/10.14412/1995-4484-2010-1401

Просмотров: 468


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)